Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAkyol, Esra Soydaş
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorBeyazyüz, Murat
dc.contributor.authorAksoy, Nurkan
dc.contributor.authorKuloğlu, Murat
dc.contributor.authorHashimoto, Kenji
dc.date.accessioned2022-05-11T14:41:05Z
dc.date.available2022-05-11T14:41:05Z
dc.date.issued2015
dc.identifier.issn1178-2021
dc.identifier.urihttps://doi.org/10.2147/NDT.S79444
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9056
dc.description.abstractBackground: Brain-derived neurotrophic factor (BDNF) is a well-established neurotrophin that plays a role in the pathophysiology of numerous psychiatric disorders. Many studies have investigated the serum BDNF levels in patients with schizophrenia. However, there are restricted data in the literature that compare the serum BDNF levels in patients with deficit and nondeficit syndromes. In this study, we aimed to compare the serum BDNF levels between schizophrenic patients with deficit or nondeficit syndrome and healthy controls. Methods: After fulfilling the inclusion and exclusion criteria, 58 patients with schizophrenia and 36 healthy controls were included in the study. The patients were grouped as deficit syndrome (N=23) and nondeficit syndrome (N=35) according to the Schedule for the Deficit Syndrome. Three groups were compared in terms of the sociodemographic and clinical variants and serum BDNF levels. Results: The groups were similar in terms of age, sex, body mass index, and smoking status. The serum BDNF levels in patients with deficit syndrome were significantly lower than those in healthy controls. In contrast, the serum BDNF levels in patients with nondeficit syndrome were similar to those in healthy controls. Conclusion: This study suggests that decreased BDNF levels may play a role in the pathophysiology of schizophrenic patients with deficit syndrome. Nonetheless, additional studies using a larger patient sample size are needed to investigate the serum BDNF levels in schizophrenic patients with deficit syndrome.en_US
dc.language.isoengen_US
dc.publisherDove Medical Press Ltden_US
dc.identifier.doi10.2147/NDT.S79444
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectbiomarkeren_US
dc.subjectneurotrophinen_US
dc.subjectpsychosisen_US
dc.subjectBdnf Levelsen_US
dc.subjectAtypical Antipsychoticsen_US
dc.subjectTardive-Dyskinesiaen_US
dc.subjectBipolar Disorderen_US
dc.subjectDiseaseen_US
dc.subjectPlasmaen_US
dc.subjectMetalloproteinasesen_US
dc.subjectPotentiationen_US
dc.subjectModulationen_US
dc.subjectDepressionen_US
dc.titleDecreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndromeen_US
dc.typearticleen_US
dc.relation.ispartofNeuropsychiatric Disease and Treatmenten_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-5770-344X
dc.authorid0000-0002-8892-0439
dc.identifier.volume11en_US
dc.identifier.startpage865en_US
dc.identifier.endpage872en_US
dc.institutionauthorAlbayrak, Yakup
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid34876196800
dc.authorscopusid29067508300
dc.authorscopusid27967486000
dc.authorscopusid7003436663
dc.authorscopusid55891056300
dc.authorscopusid55365316700
dc.authorwosidAlbayrak, Yakup/ABA-7651-2020
dc.authorwosidBEYAZYUZ, MURAT/ABA-7934-2020
dc.authorwosidHashimoto, Kenji/I-5800-2015
dc.identifier.wosWOS:000351855500001en_US
dc.identifier.scopus2-s2.0-84929168081en_US
dc.identifier.pmid25848285en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster